Vivek Ramaswamy Sells 539,650 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) major shareholder Vivek Ramaswamy sold 539,650 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $20.51, for a total value of $11,068,221.50. Following the sale, the insider owned 33,653,756 shares in the company, valued at approximately $690,238,535.56. The trade was a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Vivek Ramaswamy also recently made the following trade(s):

• On Friday, November 14th, Vivek Ramaswamy sold 1,027,670 shares of Roivant Sciences stock. The shares were sold at an average price of $20.33, for a total value of $20,892,531.10.
• On Thursday, November 13th, Vivek Ramaswamy sold 287,283 shares of Roivant Sciences stock. The stock was sold at an average price of $20.81, for a total value of $5,978,359.23.
• On Friday, September 5th, Vivek Ramaswamy sold 385,816 shares of Roivant Sciences stock. The stock was sold at an average price of $12.96, for a total transaction of $5,000,175.36.
• On Thursday, September 4th, Vivek Ramaswamy sold 194,933 shares of Roivant Sciences stock. The shares were sold at an average price of $12.92, for a total transaction of $2,518,534.36.
• On Wednesday, September 3rd, Vivek Ramaswamy sold 1,195,000 shares of Roivant Sciences stock. The shares were sold at an average price of $12.50, for a total transaction of $14,937,500.00.

Roivant Sciences Price Performance

ROIV traded up $0.27 during midday trading on Monday, reaching $20.56. 6,297,557 shares of the company’s stock were exchanged, compared to its average volume of 6,533,722. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $21.35. The stock has a market capitalization of $14.04 billion, a PE ratio of -36.71 and a beta of 1.23. The business’s 50-day moving average price is $17.00 and its 200 day moving average price is $13.36.

Institutional Investors Weigh In On Roivant Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rubric Capital Management LP increased its stake in Roivant Sciences by 14.7% in the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after purchasing an additional 2,603,260 shares during the last quarter. State Street Corp boosted its stake in Roivant Sciences by 4.8% in the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after buying an additional 911,827 shares during the last quarter. Two Seas Capital LP grew its holdings in Roivant Sciences by 4.6% in the 2nd quarter. Two Seas Capital LP now owns 10,598,040 shares of the company’s stock valued at $119,440,000 after buying an additional 461,733 shares during the period. Invesco Ltd. lifted its holdings in shares of Roivant Sciences by 3.8% during the 1st quarter. Invesco Ltd. now owns 9,880,526 shares of the company’s stock worth $99,695,000 after acquiring an additional 365,468 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Roivant Sciences by 18.0% in the third quarter. Dimensional Fund Advisors LP now owns 9,308,710 shares of the company’s stock worth $140,839,000 after acquiring an additional 1,423,074 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ROIV. The Goldman Sachs Group lifted their price objective on Roivant Sciences from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Jefferies Financial Group raised their price target on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Bank of America upped their price objective on Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a research report on Thursday, September 18th. Guggenheim reaffirmed a “buy” rating and set a $25.00 price objective on shares of Roivant Sciences in a research note on Friday. Finally, Weiss Ratings upgraded Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Saturday, October 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.56.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.